New hope for tough breast cancer: can a drug duo outperform a solo act?
NCT ID NCT06954480
Summary
This study is testing if a two-drug combination works better than a single drug for people with a specific, hard-to-treat type of advanced breast cancer that has spread. It will involve about 140 adults with a form of breast cancer that doesn't respond to standard hormone or targeted therapies and has not benefited from typical first-line treatments. The goal is to see if adding an immunotherapy drug (durvalumab) to a targeted cancer drug (datopotamab deruxtecan) can better control the cancer's growth and spread.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barts Cancer Institute, Centre of Experimental Cancer Medicine
NOT_YET_RECRUITINGLondon, EC1M 6BQ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Barts Health NHS Trust
RECRUITINGLondon, United Kingdom
Conditions
Explore the condition pages connected to this study.